-
公开(公告)号：US07070787B2
公开(公告)日：2006-07-04
申请号：US10646729
申请日：2003-08-25
IPC分类号： A61K39/385
CPC分类号： C07K16/1063 , A61K47/646 , A61K47/6841 , A61K2039/505 , Y10S530/826
摘要： The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
摘要翻译： 本发明一般涉及免疫原，特别涉及用于诱导中和大量HIV初级分离物的抗体的免疫原。 本发明还涉及使用其诱导抗HIV抗体的方法。
-
2.发明授权公开(公告)号：US07101552B2
公开(公告)日：2006-09-05
申请号：US09960717
申请日：2001-09-24
IPC分类号： A61K39/395
CPC分类号： C07K16/1063 , A61K47/646 , A61K47/6841 , A61K2039/505 , Y10S530/826
摘要： The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
摘要翻译： 本发明一般涉及免疫原，特别涉及用于诱导中和大量HIV初级分离物的抗体的免疫原。 本发明还涉及使用其诱导抗HIV抗体的方法。
-
公开(公告)号：US20080213296A1
公开(公告)日：2008-09-04
申请号：US10572312
申请日：2004-09-14
IPC分类号： A61K39/385 , C07K14/00 , C07K16/00
CPC分类号： C07K14/005 , A61K47/646 , A61K47/6811 , A61K47/6849 , A61K2039/505 , C07K14/70514 , C07K16/1063 , C12N2740/16122
摘要： The present invention relates, in general, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
摘要翻译： 本发明一般涉及用于诱导中和大量HIV初级分离物的抗体的免疫原。 本发明还涉及使用其诱导抗HIV抗体的方法。
-
4.发明授权公开(公告)号：US07033593B2
公开(公告)日：2006-04-25
申请号：US10664029
申请日：2003-09-17
IPC分类号： A61K39/00
CPC分类号： C07K16/1063 , A61K39/12 , A61K39/21 , A61K47/646 , A61K47/6841 , A61K2039/505 , C07K14/005 , C07K2317/76 , C12N2710/24143 , C12N2740/16122 , C12N2740/16134 , Y10S530/826
摘要： The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.
摘要翻译： 本发明涉及包含与配体结合的HIV包膜蛋白的免疫原，该配体上调蛋白上的CD4结合位点和CCR5结合位点中的至少一个，并与HR-2肽结合。 本发明还涉及使用这种免疫原诱导抗HIV抗体的方法。
-
公开(公告)号：US06270758B1
公开(公告)日：2001-08-07
申请号：US09168910
申请日：1998-10-08
IPC分类号： A61K4500
CPC分类号： A61K39/39 , A61K2039/541 , A61K2039/543 , A61K2039/55505 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , Y10S514/885
摘要： A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).
-
6.发明授权Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects 失效在脊椎动物受试者中基本无毒的生物活性粘膜佐剂公开(公告)号：US07041294B2
公开(公告)日：2006-05-09
申请号：US09874103
申请日：2001-06-05
CPC分类号： A61K39/39 , A61K2039/541 , A61K2039/543 , A61K2039/55505 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , Y10S514/885
摘要： A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1α(IL-1α) and interleukin-1β (IL-1β).
摘要翻译： 一种在脊椎动物受试者中引发针对抗原的免疫应答的方法，所述方法包括以下步骤：提供包含所述抗原的抗原 - 佐剂组合物和在粘膜组织中具有生物活性的基本上无毒的佐剂分子， 佐剂组合物以使得在脊椎动物受试者的粘膜组织中发生初始接触的方式给予脊椎动物受试者，由此引发免疫应答。 细胞因子是优选的佐剂。 优选的细胞因子是白细胞介素-1α（IL-1α）和白细胞介素-1β（IL-1β）。
-
公开(公告)号：US5998172A
公开(公告)日：1999-12-07
申请号：US684594
申请日：1996-07-18
申请人： Barton F. Haynes , Alejandro Aruffo , Dhavalkumar D. Patel , Michael A. Bowen , Hans Marquardt , Anthony W. Siadak
发明人： Barton F. Haynes , Alejandro Aruffo , Dhavalkumar D. Patel , Michael A. Bowen , Hans Marquardt , Anthony W. Siadak
IPC分类号： G01N33/53 , A61K31/00 , A61K38/00 , A61K39/395 , A61K45/00 , A61P37/00 , A61P37/02 , C07K14/47 , C07K14/705 , C07K16/28 , C12N5/00 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/566 , G01N33/577 , G01N33/68 , C12N5/12
CPC分类号： C07K14/705 , C07K14/70503 , C07K14/70596 , C07K16/2803 , C07K16/2896 , G01N33/68 , A61K38/00 , C07K2319/00 , C07K2319/30 , G01N2333/70503
摘要： The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.
摘要翻译： 本发明一般涉及CD6，特别是涉及存在于胸腺上皮细胞，单核细胞，活化的T细胞和多种其他细胞类型的表面上的CD6配体。 本发明还涉及抑制CD6和CD6配体相互作用的方法，以及筛选化合物抑制该相互作用的能力的方法。 本发明还涉及对CD6配体特异性的抗体及其结合片段。
-
公开(公告)号：US07972605B2
公开(公告)日：2011-07-05
申请号：US12310781
申请日：2007-09-10
IPC分类号： A61K39/285 , C12N7/01 , C12N15/863
CPC分类号： C12N15/86 , A61K39/12 , A61K39/285 , C12N7/00 , C12N2710/24143
摘要： The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response.
摘要翻译： 本发明一般涉及疫苗，特别是涉及修饰的痘苗安卡拉（MVA）病毒，涉及包含这种病毒的组合物以及使用它们诱导免疫应答的方法。
-
公开(公告)号：US20100150838A1
公开(公告)日：2010-06-17
申请号：US12647166
申请日：2009-12-24
申请人： Shari M. Ling , Lorah Perlee , Velizar T. Tchernev , Serguei Lejnine , Dhavalkumar D. Patel , Luigi Ferrucci , Ming Zhan
发明人： Shari M. Ling , Lorah Perlee , Velizar T. Tchernev , Serguei Lejnine , Dhavalkumar D. Patel , Luigi Ferrucci , Ming Zhan
IPC分类号： A61K49/00 , C12Q1/68 , C40B30/04 , C40B40/10 , G01N33/68 , A61K31/7008 , A61K31/60 , A61K31/192 , A61K31/4025 , A61K31/167 , A61K31/737 , A61K31/65
CPC分类号： G01N33/54366 , C12Q1/6883 , C12Q2600/112 , C12Q2600/158 , G01N33/6887 , G01N33/6893 , G01N2800/105
摘要： Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.
摘要翻译： 提供了用于评价骨关节炎（OA）的方法，例如用于诊断OA，确认OA的诊断，评估或预测OA的进展，确定具有OA的受试者的严重程度，以及确定受试者发生OA的风险 未来，以及可用于实践方法的数组和工具包。 在具体实例中，该方法包括确定OA风险相关分子（例如可溶性血管粘附蛋白1（sVAP-1））或白细胞介素-15（活性）的活性量（例如存在的蛋白质的量或表达量） IL-15）。 还提供了鉴定一种或多种改变OA相关分子的活性的化合物的方法，从而鉴定潜在的抗骨关节炎药物。
-
公开(公告)号：US5443964A
公开(公告)日：1995-08-22
申请号：US84406
申请日：1987-08-10
IPC分类号： C12N15/863 , C12N15/86 , C12N5/16 , C12N15/11 , C12P21/00
CPC分类号： C12N15/86 , C12N2710/24143
摘要： The invention comprises a plasmid vector, utilizing genetic material that causes high levels of expression of poxvirus genes, and the method of using this genetic material. One preferred embodiment comprises an upstream cis-acting element of a poxvirus gene encoding the major protein component of the poxvirus A-type inclusion. A second preferred embodiment of the invention comprises a downstream cis-acting element of a poxvirus gene encoding the major protein component of the poxvirus A-type inclusion. These elements are inserted upstream and downstream respectively, of selected cloned genes in the plasmid vector to obtain very high levels of expression of the cloned gene.
摘要翻译： 本发明包括使用导致痘病毒基因高水平表达的遗传物质的质粒载体，以及使用该遗传物质的方法。 一个优选的实施方案包括编码痘病毒A型包涵体的主要蛋白质成分的痘病毒基因的上游顺式作用元件。 本发明的第二个优选实施方案包括编码痘病毒A型包合物的主要蛋白质组分的痘病毒基因的下游顺式作用元件。 这些元件分别插入质粒载体中所选克隆基因的上游和下游，以获得克隆基因的非常高水平的表达。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.033 秒)
